Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517125 | 1.00 | BCAT2 (0.42) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL7197042 | 0.79 | KDM4E (0.44) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3658524 | 0.76 | KDM4E (0.46) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2762810 | 0.76 | KDM4E (0.46) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL13723957 | 0.74 | BCAT2 (0.47) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL5134567 | 0.74 | KDM4E (0.50) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL31400625 | 0.72 | IRAK4 (0.52) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL305563 | 0.72 | IRAK4 (0.52) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL11503111 | 0.71 | KDM4E (0.44) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3380036 | 0.71 | IRAK4 (0.47) | BCAT2KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | claimed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | claimed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | claimed |
| WO-2009067410-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2009-05-28 | — | — | WO | claimed |
| EP-1986622-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-11-05 | — | — | EP | claimed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | claimed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | claimed |
| WO-2007095340-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2007-08-23 | — | — | WO | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8618155-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | BCAT2 4624/4885KDM4E 3912/4885ALDH1A1 4789/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | BCAT2 4624/4885KDM4E 3912/4885ALDH1A1 4789/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | BCAT2 1108/4885KDM4E 3549/4885ALDH1A1 2909/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | BCAT2 1108/4885KDM4E 3549/4885ALDH1A1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.